Blockade of PD-L1 (B7-H1) augments human tumor-specific T cell responses in vitro - PubMed (original) (raw)
. 2006 Jul 15;119(2):317-27.
doi: 10.1002/ijc.21775.
Affiliations
- PMID: 16482562
- DOI: 10.1002/ijc.21775
Blockade of PD-L1 (B7-H1) augments human tumor-specific T cell responses in vitro
Christian Blank et al. Int J Cancer. 2006.
Abstract
Human tumors frequently escape immune destruction, despite the presence of cytotoxic T cells (CTL) recognizing tumor-associated antigens (TAA). We have previously shown that programmed death ligand-1 (PD-L1), a recently identified ligand of the B7 superfamily, is expressed on murine tumors and can inhibit antitumor immune responses. To evaluate the clinical relevance of our animal model findings, we examined human tumors and tumor-specific T cells. We found PD-L1 to be constitutively expressed on human renal cell carcinoma (RCC) cell lines and upregulated on human melanoma cell lines upon exposure to interferon-gamma. Similarly, we found binding of anti-PD-L1 monoclonal antibody (mAb) on frozen sections from RCC and melanomas, but not on normal tissues. The corresponding inhibitory receptor of PD-L1, PD-1, revealed a higher expression on tumor-infiltrating lymphocytes than on peripheral blood lymphocytes (PBL) from melanoma patients upon specific antigen stimulation. Stimulation of PBL from healthy donors with peptide-loaded dendritic cells in the presence of anti-PD-L1 mAb altered neither the total T cell numbers after expansion, nor the percentage of peptide-specific CTL, when providing a T cell help by addition of cytokines. However, when stimulating TAA-specific CTL and T helper cells with Ag-pulsed dendritic cells in the absence of exogenous cytokines, PD-L1 blockade increased the cytokine production. Similar to the data achieved in the murine system, the blockade of PD-L1 on human tumors resulted in enhanced cytolytic activity of TAA-specific CTLs and cytokine production of TAA-specific T helper cells when interacting directly with the tumor. In summary, our data suggest that PD-L1/PD-1 interactions negatively regulate T cell effector functions predominantly in the absence of exogenous cytokine support, indicating an important role for this pathway in tumor evasion.
2006 Wiley-Liss, Inc.
Similar articles
- Antibodies Against Immune Checkpoint Molecules Restore Functions of Tumor-Infiltrating T Cells in Hepatocellular Carcinomas.
Zhou G, Sprengers D, Boor PPC, Doukas M, Schutz H, Mancham S, Pedroza-Gonzalez A, Polak WG, de Jonge J, Gaspersz M, Dong H, Thielemans K, Pan Q, IJzermans JNM, Bruno MJ, Kwekkeboom J. Zhou G, et al. Gastroenterology. 2017 Oct;153(4):1107-1119.e10. doi: 10.1053/j.gastro.2017.06.017. Epub 2017 Jun 23. Gastroenterology. 2017. PMID: 28648905 - PD-L1 partially protects renal tubular epithelial cells from the attack of CD8+ cytotoxic T cells.
Waeckerle-Men Y, Starke A, Wüthrich RP. Waeckerle-Men Y, et al. Nephrol Dial Transplant. 2007 Jun;22(6):1527-36. doi: 10.1093/ndt/gfl818. Epub 2007 Mar 5. Nephrol Dial Transplant. 2007. PMID: 17339272 - Human decidual stromal cells suppress cytokine secretion by allogenic CD4+ T cells via PD-1 ligand interactions.
Nagamatsu T, Schust DJ, Sugimoto J, Barrier BF. Nagamatsu T, et al. Hum Reprod. 2009 Dec;24(12):3160-71. doi: 10.1093/humrep/dep308. Epub 2009 Sep 3. Hum Reprod. 2009. PMID: 19729380 - PD-1 blockade therapy in renal cell carcinoma: current studies and future promises.
Massari F, Santoni M, Ciccarese C, Santini D, Alfieri S, Martignoni G, Brunelli M, Piva F, Berardi R, Montironi R, Porta C, Cascinu S, Tortora G. Massari F, et al. Cancer Treat Rev. 2015 Feb;41(2):114-21. doi: 10.1016/j.ctrv.2014.12.013. Epub 2015 Jan 6. Cancer Treat Rev. 2015. PMID: 25586601 Review. - Implications of B7-H1 expression in clear cell carcinoma of the kidney for prognostication and therapy.
Thompson RH, Dong H, Kwon ED. Thompson RH, et al. Clin Cancer Res. 2007 Jan 15;13(2 Pt 2):709s-715s. doi: 10.1158/1078-0432.CCR-06-1868. Clin Cancer Res. 2007. PMID: 17255298 Review.
Cited by
- Sunitinib pretreatment improves tumor-infiltrating lymphocyte expansion by reduction in intratumoral content of myeloid-derived suppressor cells in human renal cell carcinoma.
Guislain A, Gadiot J, Kaiser A, Jordanova ES, Broeks A, Sanders J, van Boven H, de Gruijl TD, Haanen JB, Bex A, Blank CU. Guislain A, et al. Cancer Immunol Immunother. 2015 Oct;64(10):1241-50. doi: 10.1007/s00262-015-1735-z. Epub 2015 Jun 24. Cancer Immunol Immunother. 2015. PMID: 26105626 Free PMC article. - Malignant Mesothelioma Effusions Are Infiltrated by CD3+ T Cells Highly Expressing PD-L1 and the PD-L1+ Tumor Cells within These Effusions Are Susceptible to ADCC by the Anti-PD-L1 Antibody Avelumab.
Khanna S, Thomas A, Abate-Daga D, Zhang J, Morrow B, Steinberg SM, Orlandi A, Ferroni P, Schlom J, Guadagni F, Hassan R. Khanna S, et al. J Thorac Oncol. 2016 Nov;11(11):1993-2005. doi: 10.1016/j.jtho.2016.07.033. Epub 2016 Aug 17. J Thorac Oncol. 2016. PMID: 27544053 Free PMC article. - Novel strategies for inhibiting PD-1 pathway-mediated immune suppression while simultaneously delivering activating signals to tumor-reactive T cells.
Ostrand-Rosenberg S, Horn LA, Alvarez JA. Ostrand-Rosenberg S, et al. Cancer Immunol Immunother. 2015 Oct;64(10):1287-93. doi: 10.1007/s00262-015-1677-5. Epub 2015 Mar 20. Cancer Immunol Immunother. 2015. PMID: 25792524 Free PMC article. Review. - Immunotherapy for prostate cancer: an emerging treatment modality.
Drake CG. Drake CG. Urol Clin North Am. 2010 Feb;37(1):121-9, Table of Contents. doi: 10.1016/j.ucl.2009.11.001. Urol Clin North Am. 2010. PMID: 20152525 Free PMC article. Review. - A Novel Type of PD-L1 Inhibitor rU1 snRNPA From Human-Derived Protein Scaffolds Library.
Ma C, Qiao S, Liu Z, Shan L, Liang C, Fan M, Sun F. Ma C, et al. Front Oncol. 2021 Nov 29;11:781046. doi: 10.3389/fonc.2021.781046. eCollection 2021. Front Oncol. 2021. PMID: 34912719 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials